Detecting HPV DNA in Anal and Cervical Cancers

Recruiting now

Conditions studied: Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, Uterine Cervical Cancer

In brief

This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more information about HPV-associated cancers and how they respond to treatment. Participation in this study will last approximately 2 years.

Key facts

Study ID

NCT04857528

Run by

University of Chicago

People needed

20

Starts

2020-10-06

Expected to finish

2027-11-15

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage I-III anal cancer or stage I-IVA cervical cancer that is p16+ based on immunohistochemistry.
• Age ≥ 18 years
• Planned to undergo radiation therapy as definitive treatment, with or without concurrent systemic therapy

You may not qualify if…

• Anal carcinoma not associated with HPV-16, 18, 31, 33, or 35 will be removed from the
• Planned to undergo radiation therapy as an adjuvant or post-operative therapy

Where it is running

• University of Illinois at Chicago — Chicago, Illinois, United States (enrolling)
• University of Chicago — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.